We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA to Rescind Breakthrough Therapy Designation for Protagonist’s Blood Cancer Drug
FDA to Rescind Breakthrough Therapy Designation for Protagonist’s Blood Cancer Drug
The FDA intends to revoke Protagonist Therapeutics’ Breakthrough Therapy designation for rusfertide as a treatment for a rare blood cancer that causes bone marrow to produce excess red blood cells, the company said.